PRTA · XBRL financial data
Prothena Corporation Public Limited Company financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (PRTA's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 1 | 201 | 54 | 91 | 135 | 10 |
| Research and development | 75 | 82 | 136 | 221 | 223 | 135 |
| General and administrative | 39 | 46 | 50 | 62 | 67 | 59 |
| Total operating expenses | 114 | 129 | 185 | 282 | 290 | 224 |
| Operating income (loss) | (113) | 72 | (132) | (191) | (155) | (215) |
| Other income (expense) | (0) | (0) | (0) | (0) | (0) | (0) |
| Income tax expense (benefit) | (0) | 5 | (9) | (13) | (7) | 43 |
| Net income (loss) | (111) | 67 | (117) | (147) | (122) | (244) |
| Earnings per share, basic USD per share | (2.78) | 1.51 | (2.47) | (2.76) | (2.27) | (4.53) |
| Earnings per share, diluted USD per share | (2.78) | 1.38 | (2.47) | (2.76) | (2.27) | (4.53) |
| Weighted average shares, basic millions of shares | 40 | 44 | 47 | 53 | 54 | 54 |
| Weighted average shares, diluted millions of shares | 40 | 48 | 47 | 53 | 54 | 54 |
Balance sheet
CSVFiscal years (PRTA's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 295 | 579 | 710 | 619 | 471 | 308 |
| Accounts receivable | 0 | 0 | 0 | 5 | 0 | — |
| Prepaid and other current assets | 3 | 6 | 9 | 14 | 14 | 8 |
| Total current assets | 299 | 585 | 719 | 639 | 485 | 315 |
| Property and equipment, net | 3 | 2 | 2 | 4 | 3 | 2 |
| Right-of-use asset | 18 | 12 | 6 | 12 | 11 | 8 |
| Total assets | 333 | 609 | 758 | 696 | 547 | 327 |
| Accounts payable | 4 | 4 | 9 | 25 | 8 | 6 |
| Total current liabilities | 26 | 33 | 50 | 57 | 49 | 41 |
| Lease liability, non-current | 12 | 6 | 0 | 11 | 8 | 5 |
| Total liabilities | 149 | 143 | 136 | 135 | 60 | 46 |
| Accumulated deficit | (783) | (716) | (833) | (980) | (1,102) | (1,346) |
| Total stockholders' equity | 184 | 466 | 622 | 561 | 487 | 280 |
| Total liabilities and equity | 333 | 609 | 758 | 696 | 547 | 327 |
| Common shares outstanding (cover page) millions of shares | 40 | 47 | 53 | 54 | 54 | 54 |
Cash flows
CSVFiscal years (PRTA's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (111) | 67 | (117) | (147) | (122) | (244) |
| Stock-based compensation | 22 | 25 | 31 | 41 | 46 | 38 |
| Depreciation and amortization | 2 | 1 | 1 | 1 | 1 | 1 |
| Net cash from operating activities | (80) | 93 | (109) | (134) | (150) | (164) |
| Net cash from investing activities | (0) | (1) | (0) | (3) | (0) | (0) |
| Proceeds from issuing common stock | 0 | 78 | — | — | — | — |
| Net cash from financing activities | 0 | 190 | 241 | 45 | 2 | (0) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Prothena Corp Public | 288 | 1 | (25)* | 51.3M | 11.5 quarters | 10-QJun 30, 2026 |
| Altimmune | 63 | not reported | (24)* | 194.5M | 13.5 quarters | 10-QJun 30, 2026 |
| Usana Health Sciences | 169 | 223 | 23* | 18.5M | — | 10-QJul 4, 2026 |
| Rigel Pharmaceuticals | 61 | 79 | 31* | 18.7M | — | 10-QJun 30, 2026 |
| Aura Biosciences | 68 | not reported | (33)* | 103.7M | 2.1 quarters | 10-QJun 30, 2026 |
| Amarin | 157 | 40 | 9.2* | not reported | — | 10-QSep 30, 2026 |
| Nektar Therapeutics | 39 | 10 | (76)* | 34.1M | 9.0 quarters | 10-QJun 30, 2026 |
| Northwest Biotherapeutics | 0.6 | 0.8 | (7.2)* | 1.7B | 0.1 quarters | 10-QJun 30, 2026 |
| Emergent BioSolutions | 176 | 110 | 100* | 51.4M | — | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.